Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

EAST SETAUKET, N.Y., Jan. 5, 2016 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced last week that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) inAsia to Taipei Medical University (TMU). LB-1...